Mika Lindvall

Biochemistry, Genetics and Molecular Biology · Life Sciences

24h-index4.1kcitations60works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(18), Cancer Mechanisms and Therapy(15), Synthesis and biological activity(13), Computational Drug Discovery Methods(11), Protein Kinase Regulation and GTPase Signaling(6)

Publications60 total

Supplementary Table 2 from Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers
2023Open Access
Supplementary Table 2 from Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers
2023Open Access
Data from Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers
2023Open Access
Supplementary Methods from Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers
2023Open Access
Supplementary Figures 1 - 4 from Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers
2023Open Access
Data from Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers
2023Open Access
Supplementary Methods from Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers
2023Open Access
Supplementary Figure Legends from Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers
2023Open Access
Supplementary Figures 1 - 4 from Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers
2023Open Access
Supplementary Table 1 from Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers
2023Open Access
Supplementary Table 1 from Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers
2023Open Access
Supplementary Figure Legends from Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers
2023Open Access
Supplementary Figures 1 - 5, Tables 1 - 2 from Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers
2023Open Access
Data from Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers
2023Open Access
Data from Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers
2023Open Access
Supplementary Figures 1 - 5, Tables 1 - 2 from Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers
2023Open Access
Towards the sustainable discovery and development of new antibiotics
Nature Reviews Chemistry·2021· 1.1k citedOpen Access
Synthesis and Structure–Activity Relationship of Tetra-Substituted Cyclohexyl Diol Inhibitors of Proviral Insertion of Moloney Virus (PIM) Kinases
Journal of Medicinal Chemistry·2020· 6 citedOpen Access
AI-based recommendations for drug discovery
2020
An Artificial Intelligence Approach to Proactively Inspire Drug Discovery with Recommendations
Journal of Medicinal Chemistry·2020· 31 cited
page 1 of 3Next →

Frequent Co-authors

Jiong Lan(16), Stephen E. Basham(14), Cynthia M. Shafer(14), B.A. Appleton(13), Laura V. Doyle(12), Anne B. Jefferson(12), Ida Aronchik(10), Elizabeth Ornelas(10), Mercedita Del Rosario(9), William F. Estacio(9), Catherine A. Luu(9), Eleni Venetsanakos(9), Paul Feucht(8), Cornelia Bellamacina(8), Ari M. P. Koskinen(8), Kenneth Crawford(8), Gordana Atallah(7), Wooseok Han(6), Pablo D. García(5), Gisele Nishiguchi(5)